Capricor Therapeutics is facing a securities fraud class action alleging it failed to disclose post-hoc changes to the statistical analysis plan behind its Deramiocel BLA. The FDA's July 27, 2026 briefing documents triggered a 64.5% single-day stock drop, and investors have until September 28 to seek lead plaintiff status in the Southern District of California case.
Capricor Therapeutics Inc. faces a securities fraud class action alleging it concealed post-hoc changes to the statistical analysis plan underpinning its Deramiocel Biologics License Application, a disclosure that erased 64.5% of the company's market value in a single session.
The complaint, captioned Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385, was filed in the U.S. District Court for the Southern District of California and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Bleichmar Fonti & Auld LLP, which announced the action, said investors have until September 28, 2026 to move for lead plaintiff status. "The final version of the statistical analysis plan was not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon," the complaint alleges, citing FDA briefing documents.
The alleged class period runs from December 17, 2025 through July 26, 2026, according to a parallel notice from Kaplan Fox & Kilsheimer LLP. At issue is Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. Capricor submitted the BLA in late 2024; the FDA responded in July 2025 with a Complete Response Letter stating the application did not meet the statutory requirement for substantial evidence of effectiveness and that additional clinical data was needed. The complaint alleges Capricor then revised the pre-specified plan governing its primary endpoint, PUL 2.0, shortly before the database was unlocked and unblinded, without FDA agreement.
The stock fell $12.70 to $7.00 on July 27, 2026, from a prior close of $19.70, after the FDA released briefing documents ahead of an advisory committee meeting. Two days later, a non-binding 9-3 panel vote concluded the available evidence did not support Deramiocel's efficacy for treating DMD-associated cardiomyopathy. Shares dropped a further $2.38, or 36%, to $4.19 on July 30.
The litigation turns on a narrow methodological question with an outsized legal consequence. A pre-specified analysis plan fixes the statistical tests before data are unblinded, which limits the ability to select a favorable result after the fact. Changing the methodology for calculating a primary endpoint close to unblinding is the specific conduct the FDA flagged, and it is the same conduct the plaintiffs characterize as a material misstatement. Capricor has not yet disclosed a response to the complaint.
For holders, the near-term signal is procedural rather than clinical: the September 28 deadline will determine which firm leads the case and how aggressively it is litigated, while the underlying efficacy question remains unresolved. Capricor's next clinical checkpoint is any FDA action on the resubmitted Deramiocel BLA, which has not yet been disclosed.
This article is for informational purposes only and does not constitute investment advice.
